View Older Stories View More Recent Stories
-
Lilly plans $3 billion manufacturing facility in Netherlands
-
Bernstein on Eli Lilly (LLY): 'Stock Limited Near-Term by Poli(cy)tics'
-
Eli Lilly (LLY) PT Raised to $976 at Jefferies
-
Eli Lilly raises annual revenue guidance amid strong weight-loss drug demand
-
Eli Lilly & Co. (LLY) Tops Q3 EPS by 113c; raises guidance
-
Eli Lilly poised for strong quarter despite profit hit from one-time charge
-
Eli Lilly & Co. (LLY) call put ratio 2.2 calls to 1 put into quarter results
-
Eli Lilly invests $1.2 billion to expand Puerto Rico manufacturing site
-
LillyDirect partners with Walmart for Zepbound pickup option
-
Eli Lilly builds supercomputer with NVIDIA for drug discovery
-
Lilly receives FDA approval for single-injection Omvoh maintenance dosing
-
Eli Lilly & Co. (LLY) Declares $1.50 Quarterly Dividend; 0.7% Yield
-
Lilly's Omvoh shows bowel urgency improvements in ulcerative colitis study
-
Eli Lilly submits data for EBGLYSS eight-week dosing to FDA
-
Eli Lilly (LLY) PT Raised to $930 at BMO Capital
-
Nektar Therapeutics (NKTR) PT Raised to $105 at B.Riley
-
Nektar Therapeutics (NKTR) Strength Attributed to Rumor
-
Lilly's Verzenio shows survival benefit in early breast cancer study
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY) Amid GLP-1 Pricing Uncertainty
-
Eli Lilly & Co. (LLY) call put ratio 4.6 calls to 1 put into headlines
-
Stocks expected to have increasing option volume: LLY NVO VKTX AXP OZK TFC SLB FITB HBAN ALLY CME RGTI QUBT IONQ
-
After-hours movers: CSX Corp, Interactive Brokers, Novo Nordisk, Lilly
-
Eli Lilly Shares Fall 2.7%, Novo Drops 2.8%; Trump: Ozempic, Fatloss Drug Prices To Come Down 'pretty Fast'
-
Citizens Reiterates Market Outperform Rating on ProQR Therapeutics N.V. (PRQR)
-
Erste Group Upgrades Eli Lilly (LLY) to Buy, 'expect Eli Lilly to gain market share relative to its peers'
-
Lilly to present Verzenio survival data at ESMO meeting
-
Abbvie (ABBV) PT Raised to $284 at Piper Sandler
-
TD Cowen says this is 'a must-own stock'
-
Eli Lilly (LLY) PT Raised to $948 at Guggenheim
-
Citizens Reiterates Market Outperform Rating on Terns Pharmaceuticals (TERN)
-
Former FDA vaccine regulator Peter Marks joins Eli Lilly
-
Lilly reports four-year remission data for ulcerative colitis drug
-
TD Cowen Calls Eli Lilly (LLY) 'A Must-Own Stock'
-
Eli Lilly & Co. (LLY) call put ratio 2.4 calls to 1 put with a focus on a spreader of November 850 calls
-
US Pausing Pharma Duties While Negotiations Ongoing - Politico
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
Fact Sheet: President Donald J. Trump Announces First Deal to Bring Most-Favored-Nation Pricing to American Patients
-
Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
-
Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
-
M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip
-
Guggenheim Reiterates Buy Rating on Eli Lilly (LLY)
-
CFRA Upgrades Eli Lilly (LLY) to Buy (earlier)
-
Lilly opens new Gateway Labs facility in San Diego
-
Novo Nordisk: Diabetes and obesity GLP-1 portfolio still attractive says Bernstein
-
Bernstein Reiterates Outperform Rating on Eli Lilly (LLY)
-
Lilly to build $6.5 billion manufacturing facility in Houston
-
UBS slashes global GLP-1 sales estimate for 2030 on softer outlook
-
Eli Lilly partners with Prellis Biologics on antibody drug discovery
-
Walmart (WMT) Adds Home Delivery for Ozempic, Other Refrigerated Drugs - Bloomberg
